Pyruvate Kinase M2 Protects Heart from Pressure Overload‐Induced Heart Failure by Phosphorylating RAC1
Le Ni,Bowen Lin,Lingjie Hu,Ruoyu Zhang,Fengmei Fu,Meiting Shen,Jian Yang,Dan Shi
DOI: https://doi.org/10.1161/JAHA.121.024854
2022-06-05
Abstract:Background Heart failure, caused by sustained pressure overload, remains a major public health problem. PKM (pyruvate kinase M) acts as a rate‐limiting enzyme of glycolysis. PKM2 (pyruvate kinase M2), an alternative splicing product of PKM, plays complex roles in various biological processes and diseases. However, the role of PKM2 in the development of heart failure remains unknown. Methods and Results Cardiomyocyte‐specific Pkm2 knockout mice were generated by crossing the floxed Pkm2 mice with α‐MHC (myosin heavy chain)‐Cre transgenic mice, and cardiac specific Pkm2 overexpression mice were established by injecting adeno‐associated virus serotype 9 system. The results showed that cardiomyocyte‐specific Pkm2 deletion resulted in significant deterioration of cardiac functions under pressure overload, whereas Pkm2 overexpression mitigated transverse aortic constriction‐induced cardiac hypertrophy and improved heart functions. Mechanistically, we demonstrated that PKM2 acted as a protein kinase rather than a pyruvate kinase, which inhibited the activation of RAC1 (rho family, small GTP binding protein)‐MAPK (mitogen‐activated protein kinase) signaling pathway by phosphorylating RAC1 in the progress of heart failure. In addition, blockade of RAC1 through NSC23766, a specific RAC1 inhibitor, attenuated pathological cardiac remodeling in Pkm2 deficiency mice subjected to transverse aortic constriction. Conclusions This study revealed that PKM2 attenuated overload‐induced pathological cardiac hypertrophy and heart failure, which provides an attractive target for the prevention and treatment of cardiomyopathies. Nonstandard Abbreviations and Acronyms β‐MHC β‐myosin heavy chain cKO conditional knockout cTnT cardiac troponin T MAPK mitogen‐activated protein kinase NRCM neonatal rat cardiomyocytes PKM1 pyruvate kinase M1 PKM2 pyruvate kinase M2 RAC1 rho family, small GTP binding protein Clinical Perspective What Is New? PKM2 (pyruvate kinase M2) deficiency in cardiomyocytes accelerates the development of pressure overload‐induced heart failure. PKM2 overexpression alleviates pressure overload‐induced heart failure by modulating RAC1 (rho family, small GTP binding protein)‐MAPK (mitogen‐activated protein kinase) signaling pathway. PKM2 phosphorylates RAC1 in cardiomyocytes as a protein kinase, contributing to its cardioprotective effects. What Are the Clinical Implications? This study unveils PKM2 as a cardioprotective protein kinase in maintaining cardiac homeostasis under hemodynamic stress overload, which offers a potential therapeutic target for heart failure. Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >30 million people globally. 1 Although guideline‐recommended medical therapy has lowered the mortality of patients with HF, 2 , 3 the overall mortality and rehospitalization rates are still high. 3 Numerous studies have been undertaken to discover new mechanisms and develop therapeutic strategies aiming to improve the prognosis of HF. However, so far, few conceptual breakthroughs have been made. 4 , 5 Therefore, it's still urgent to reveal new and pivotal mechanisms contributing to HF. Pyruvate kinase M (PKM) is the key enzyme responsible for converting phosphoenolpyruvate to pyruvate at the final step of glycolysis. 6 PKM1 and PKM2, 2 alternative‐splicing isoforms of the PKM gene, 7 , 8 differ significantly in their protein structure and biochemical functions. 9 , 10 The tetramer of PKM2 exerts pyruvate kinase activity in glucose metabolism, whereas its monomer and dimer participate in multiple signaling pathways and cellular processes such as proliferation, -Abstract Truncated-